<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563170</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.072</org_study_id>
    <nct_id>NCT03563170</nct_id>
  </id_info>
  <brief_title>QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine</brief_title>
  <official_title>Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral &amp; Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable &amp; Untransplantable HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination&#xD;
      therapy in subjects with advanced, unresectable, and untransplantable HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be administered in two phases, an induction and a maintenance phase. Subjects&#xD;
      will continue induction treatment for up to 1 year. Those who have a CR in the induction&#xD;
      phase will enter the maintenance phase of the study. Subjects who experience ongoing SD or an&#xD;
      ongoing PR at 1 year may enter the maintenance phase at the Investigator's and Sponsor's&#xD;
      discretion. Subjects may remain in the maintenance phase of the study for up to 1 year.&#xD;
      Treatment in the study will be discontinued if the subject experiences confirmed PD or&#xD;
      unacceptable toxicity (not corrected with dose reduction), withdraws consent, undergoes liver&#xD;
      transplantation or surgical resection, or if the Investigator feels it is no longer in the&#xD;
      subject's best interest to continue treatment. Subjects with an initial assessment of PD may,&#xD;
      at the discretion of the Investigator, continue to receive study treatment until PD is&#xD;
      confirmed. The maximum time on study treatment is 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Enrollment not initiated&#xD;
  </why_stopped>
  <start_date type="Actual">May 25, 2018</start_date>
  <completion_date type="Actual">August 23, 2019</completion_date>
  <primary_completion_date type="Actual">August 23, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the overall safety profile in subjects with advanced, unresectable, untransplantable HCC who have progressed or experienced unacceptable toxicity on prior sorafenib treatment. Measured / reported based on the tumor size imaging per RECIST 1.1.</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival from baseline to progression, per RECIST 1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 2 Randomized Component</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 2 Single Arm Component</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR for Phase 1b and Phase 2 Randomized Component</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS for Phase 1b and Phase 2 Single Arm Component</measure>
    <time_frame>1 year</time_frame>
    <description>Progression Free Survival from baseline to progression per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival from first treatment to date of death (any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>1 year</time_frame>
    <description>Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS for Phase 2 Randomized Component</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free Survival from baseline to progression per irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety for Phase 2 Randomized and Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per irRC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <condition>Hepatocellular Carcinoma Recurrent</condition>
  <arm_group>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNKâ„¢, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>Ad5 [E1-, E2b-]-CEA</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK for infusion</intervention_name>
    <description>NK-92 [CD16.158V, ER IL-2]</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>avelumab</intervention_name>
    <description>Recombinant human anti-PD-L1 IgG1 monoclonal antibody</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>anhydrous</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU; Fluorouracil</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin calcium salt</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <description>ABRAXANEÂ® [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>NEXAVARÂ® tablets, for oral use</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
    <arm_group_label>Sorafenib Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic Body Radiation Therapy</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldoxorubicin hydrochloride</intervention_name>
    <description>HCl</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury vaccine</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6207</intervention_name>
    <description>CEA yeast vaccine</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Brachyury yeast vaccine</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>ERBITUXÂ® injection, for IV infusion)</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>N-803</intervention_name>
    <description>Recombinant human super agonist IL-15 complex [also known as IL-15N72D:IL- 15RÎ±Su/IgG1 Fc complex]</description>
    <arm_group_label>NANT Hepatocellular Carcinoma Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             IRB or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          3. Histologically-confirmed advanced, unresectable and untransplantable HCC.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          5. Have at least 1 measurable lesion of â‰¥ 1.0 cm.&#xD;
&#xD;
          6. Must have Child-Pugh class A only.&#xD;
&#xD;
          7. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen&#xD;
             following the conclusion of the most recent anticancer treatment and be willing to&#xD;
             release the specimen for prospective and exploratory tumor molecular profiling. If an&#xD;
             historic specimen is not available, the subject must be willing to undergo a biopsy&#xD;
             during the screening period, if considered safe by the Investigator. If safety&#xD;
             concerns preclude collection of a biopsy during the screening period, a tumor biopsy&#xD;
             specimen collected prior to the conclusion of the most recent anticancer treatment may&#xD;
             be used.&#xD;
&#xD;
          8. Must be willing to provide blood samples prior to the start of treatment on this study&#xD;
             for prospective tumor molecular profiling and exploratory analyses.&#xD;
&#xD;
          9. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of&#xD;
             treatment for exploratory analyses, if considered safe by the Investigator.&#xD;
&#xD;
         10. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
         11. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and&#xD;
             non-sterile male subjects must agree to use a condom for up to 4 months after&#xD;
             treatment. Effective contraception includes surgical sterilization (eg, vasectomy,&#xD;
             tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with&#xD;
             spermicide, intrauterine devices (IUDs), and abstinence.&#xD;
&#xD;
         12. Any prior locoregional therapy allowed.&#xD;
&#xD;
             Phase 1b only&#xD;
&#xD;
         13. Must have progressed or experienced unacceptable toxicity on sorafenib prior to&#xD;
             enrollment in the study.&#xD;
&#xD;
             Phase 2 single-arm component only&#xD;
&#xD;
         14. Must have progressed on or after sorafenib monotherapy in the randomized phase 2&#xD;
             portion of the study OR progressed or experienced unacceptable toxicity on sorafenib&#xD;
             prior to enrollment on the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          2. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, or autoimmune disease associated with lymphoma).&#xD;
&#xD;
          3. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          5. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. Absolute neutrophil count &lt; 1,000 cells/mm^3&#xD;
&#xD;
               2. Medically uncorrectable grade 3 anemia (hemoglobin &lt; 8 g/dL).&#xD;
&#xD;
               3. Platelet count &lt; 75,000 cells/mm^3.&#xD;
&#xD;
               4. Total bilirubin greater than the upper limit of normal (ULN; unless the subject&#xD;
                  has documented Gilbert's syndrome).&#xD;
&#xD;
               5. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])&#xD;
&#xD;
                  â‰¥ 2.5 Ã— ULN (â‰¥ 5 Ã— ULN in subjects with liver metastases).&#xD;
&#xD;
               6. Alkaline phosphatase levels &gt; 2.5 Ã— ULN (&gt; 5 Ã— ULN in subjects with liver&#xD;
                  metastases, or &gt;10 Ã— ULN in subjects with bone metastases).&#xD;
&#xD;
               7. Serum creatinine &gt; 2.0 mg/dL or 177 Î¼mol/L.&#xD;
&#xD;
               8. International normalized ratio (INR) â‰¥ 2.0&#xD;
&#xD;
               9. Serum anion gap &gt; 16 mEq/L or arterial blood with pH &lt; 7.3.&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
          7. Episode of portal hypertension-related GI bleeding within prior 6 months.&#xD;
&#xD;
          8. Serious myocardial dysfunction defined by echocardiogram (ECHO) as absolute left&#xD;
             ventricular ejection fraction (LVEF) 10% below the institution's lower limit of normal&#xD;
             (LLN).&#xD;
&#xD;
          9. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
         10. Positive results of screening test for human immunodeficiency virus (HIV).&#xD;
&#xD;
         11. Participants with dual active hepatitis B virus (HBV) infection (hepatitis B surface&#xD;
             antigen [HBsAg] positive [+] and /or detectable HBVDNA) and hepatitis C virus (HCV)&#xD;
             infection (anti-HCV antibody [Ab] [+] and detectable HCV ribonucleic acid [RNA]) at&#xD;
             study entry. Subjects with chronic infection by HCV who are treated with&#xD;
             anti-hepatitis B therapy (successfully or treatment failure) or untreated are allowed&#xD;
             on study. Controlled (treated) hepatitis B subjects will be allowed if they meet the&#xD;
             following criteria:&#xD;
&#xD;
               1. Antiviral therapy for HBV must be given for at least 12 weeks and HBV viral load&#xD;
                  must be less than 100 IU/mL prior to first dose of study drug; subjects on active&#xD;
                  HBV therapy with viral loads under 100 IU/mL should stay on the same therapy&#xD;
                  throughout study treatment.&#xD;
&#xD;
               2. Subjects who are positive for anti-hepatitis B core Abs (HBc[+]), negative for&#xD;
                  HBsAg, negative for anti-hepatitis B surface Ab (HBs[-]), and have a HBV viral&#xD;
                  load under 100 IU/mL do not require HBV anti-viral prophylaxis.&#xD;
&#xD;
               3. Subjects with successful HCV treatment are allowed as long as there are at least&#xD;
                  4 weeks between achieving sustained viral response (SVR) and start of study drug.&#xD;
&#xD;
         12. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         13. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         14. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         15. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including&#xD;
             ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit&#xD;
             products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin,&#xD;
             rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study&#xD;
             day 1.&#xD;
&#xD;
         16. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         17. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 14 days prior to screening for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
         18. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         19. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         20. Pregnant and nursing women.&#xD;
&#xD;
             Phase 2 randomized component only -&#xD;
&#xD;
         21. Prior sorafenib treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

